Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
J Clin Immunol. 2013 May;33(4):838-46. doi: 10.1007/s10875-012-9856-z. Epub 2012 Dec 29.
Existing ways of assessing CVID patients at risk of pulmonary infections are not universally accepted. The need to identify additional prognostic factors allowed us to evaluate the anti-polysaccharide IgA and IgM responses in 125 CVID patients immunized with the 23-valent pneumococcal polysaccharide (PS) vaccine (Pneumovax(®)).
We used a new anti-PS23 IgM and IgA ELISA assay, which evaluates a global response to all 23 polysaccharides contained in Pneumovax(®).
Anti-PS23 IgM and/or IgA antibodies were detectable in a minority of CVID patients. Antibody responses were correlated to B cell subpopulations and serum immunoglobulin concentrations. The non responders had a higher incidence of pneumonia and bronchiectasis and responders had the lowest incidence of respiratory complications.
This new ELISA assay allows for studying vaccine response in patients on Ig replacement therapy. This test also is an additional method of evaluation of specific antibody responses representing a valuable contribution to identify prognostic marker in CVID patients.
评估易患肺部感染的 CVID 患者的现有方法尚未被普遍接受。需要确定其他预后因素，这使我们能够评估 125 名接受 23 价肺炎球菌多糖（PS）疫苗（Pneumovax®）免疫的 CVID 患者的抗多糖 IgA 和 IgM 反应。
我们使用了一种新的抗 PS23 IgM 和 IgA ELISA 检测法，该方法评估了 Pneumovax®中包含的所有 23 种多糖的总体反应。
少数 CVID 患者可检测到抗 PS23 IgM 和/或 IgA 抗体。抗体反应与 B 细胞亚群和血清免疫球蛋白浓度相关。无应答者肺炎和支气管扩张的发生率较高，而应答者呼吸道并发症的发生率最低。
这种新的 ELISA 检测法可用于研究接受 Ig 替代治疗的患者的疫苗反应。该检测法也是评估特异性抗体反应的另一种方法，为识别 CVID 患者的预后标志物提供了有价值的贡献。
